Ionis Pharmaceuticals: Promising Market Growth with Tryngolza Approval and Advancing Clinical Trials

William Blair analyst Myles Minter has reiterated their bullish stance on IONS stock, giving a Buy rating on April 8.

Myles Minter has given his Buy rating due to a combination of factors that highlight the potential of Ionis Pharmaceuticals. The recent webinar hosted by Ionis shed light on the promising real-world application of Tryngolza, their ApoC-III-silencing antisense oligonucleotide, which has been approved for familial chylomicronemia syndrome (FCS). This approval is a significant milestone and sets the stage for its first market launch, which is expected to drive growth for the company.
Furthermore, Ionis is advancing its clinical trials with Phase III studies of olezarsen in severe hypertriglyceridemia (sHTG), with results anticipated in the latter half of 2025. These studies, CORE-1 and CORE-2, are pivotal for potential approval in sHTG, and their success could significantly enhance Ionis’s market position. The positive feedback from experts and the strategic advancements in their clinical pipeline contribute to Minter’s optimistic outlook on Ionis’s stock, justifying the Buy rating.

In another report released on April 8, Needham also maintained a Buy rating on the stock with a $60.00 price target.

Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IONS in relation to earlier this year.